Entries by Organicell

FDA Grants Organicell Expanded Access to Treat COVID-19 Patients with ZofinTM

Miami, FL (September 29, 2020) – Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that the U.S. Food and Drug Administration (FDA) granted expanded access for an intermediate size population allowing its proprietary therapeutic, Zofin for the treatment of COVID-19. This expanded access protocol will provide […]

Interview with the CEO: Organicell Regenerative Medicine, Inc. (OTCMKTS:BPSR)

Click Here for PDF Organicell Regenerative Medicine, Inc. (OTCMKTS:BPSR)  ALBERT MITRANI has been Chief Operating Officer, President and board member at Organicell Regenerative Medicine, Inc. since April 2018, and he also is the Chairman of the board, Chief Executive Officer, Secretary and Treasurer at Organicell Regenerative Medicine, Inc. — alternate name Biotech Products since June […]

Three New COVID-19 Patients Treated with Zofin™ Report Improvement

Organicell Commences Phase I/II Clinical Trial Enrollment Miami, FL (September 2, 2020) – Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that the U.S. Food and Drug Administration (FDA) granted emergency, expanded access approval to treat two mild to moderate COVID-19 patients and one “Long Hauler” […]

First Reported “Long-Hauler” Post COVID-19 Patient Treated with Zofin™ Produces Excellent Preliminary Results

Miami, FL (August 20, 2020) – Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that the U.S. Food and Drug Administration (FDA) granted emergency, expanded access approval to treat one “long-hauler” patient on August, 1, 2020, and two additional patient approvals on August 17, 2020. In […]

Organicell Phase I/II Clinical Trial Update

Lead Therapeutic Candidate To Be Named Zofin™ Miami, FL (August 18, 2020) — Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it has partnered with Alternative Research Associates, LLC and Larkin Hospital in Miami, FL to initiate a randomized, double-blinded, placebo-controlled phase I/II […]

Organicell Completes Capital Raise from Retrograde Investments

Miami, FL (August 13, 2020) — Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it has completed an initial capital raise from Retrograde Investments LLC. The proceeds from the investment will be used to fund the costs associated with bringing current all financial audits […]

Outpatient Treatment of Subacute Post-COVID-19 Syndrome with Organicell Flow Produces Excellent Preliminary Results

A PRACTICING SURGEON FROM CORDELE, GEORGIA TELLS HIS PERSPECTIVE AND JOURNEY OF SUFFERING AND THEN RECOVERING FROM COVID-19 INFECTION IN HIS OWN WORDS. By: Dr. Allen Meglin, Treating Physician I was admitted to the hospital with COVID-19 on June 8, 2020 after a week of progressive COVID-19 symptoms, including loss of taste sensation, dry cough, […]

FDA Approves Two Emergency INDs for COVID-19 Outpatient Therapy

FIRST REPORTED EIND ISSUED FOR OUTPATIENT COVID-19 THERAPY MIAMI, Aug. 06, 2020 — Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) approved two outpatient Emergency Investigational New Drug Applications (eINDs) for treating mild to moderate respiratory distress […]